ESMO Conference Poster Presentation Conclusions Conclusion
• Increases in both T and B cell immune infiltration in tumors are associated with >10% tumor reduction in patients treated with MVP-S based therapy,
• Natural antibodies against survivin peptides can be detected in some cancer patients prior to MVP-S treatment and can be further increased by MVP-S treatment,
• MVP-S-based treatment can elicit de novo antibody responses against all 5 survivin antigens. Immune responses were maintained for at least 6 months after treatment initiation,
• Antigen-specific humoral responses to MVP-S antigens are more prominent in patients with >10% tumor reduction,
Results of this study provide new insight into the mechanism of action of MVP-S and suggest that both cellular and humoral survivin-specific immune responses are important for the anti-cancer efficacy driven by MVP-S based immunotherapy.